Aligos Therapeutics (ALGS) Income from Continuing Operations (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Income from Continuing Operations for 8 consecutive years, with -$1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations rose 90.52% year-over-year to -$1.5 million; the trailing twelve-month figure through Jun 2026 stood at -$70.6 million (up 4.79% YoY), and the FY2025 full-year result was -$18.9 million, up 85.62% from the prior year.
• Income from Continuing Operations advanced to -$1.5 million in Q2 2026 per ALGS's latest filing, from -$23.0 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at $43.1 million in Q1 2025 and bottomed at -$82.1 million in Q4 2024.
• Historically, Income from Continuing Operations has averaged -$19.9 million across 5 years, with a median of -$19.6 million in 2022.
• The widest YoY moves for Income from Continuing Operations: up 223.59% in 2025, down 413.44% in 2025.
• Over 5 years, Income from Continuing Operations stood at -$21.9 million in 2022, then slipped by 27.44% to -$27.9 million in 2023, then sank by 194.53% to -$82.1 million in 2024, then surged by 82.29% to -$14.6 million in 2025, then jumped by 89.66% to -$1.5 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered -$1.5 million, -$23.0 million, and -$14.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.